186 related articles for article (PubMed ID: 16454430)
1. Wyeth responds to criticism.
Stiles GM
Md Med; 2005; 6(4):5, 7-8; author reply 8. PubMed ID: 16454430
[No Abstract] [Full Text] [Related]
2. Wyeth Pharmaceutical's perspective on vaccine production.
Stiles GL
Md Med; 2005; 6(1):22-3. PubMed ID: 15869103
[No Abstract] [Full Text] [Related]
3. The fragility of the U.S. vaccine supply.
Sloan FA; Berman S; Rosenbaum S; Chalk RA; Giffin RB
N Engl J Med; 2004 Dec; 351(23):2443-7. PubMed ID: 15575064
[No Abstract] [Full Text] [Related]
4. The National Childhood Vaccine Injury Act and the supreme court's interpretation.
Blake V
Virtual Mentor; 2012 Jan; 14(1):31-4. PubMed ID: 23116914
[No Abstract] [Full Text] [Related]
5. Triage in the nation's medicine cabinet: the puzzling scarcity of vaccines and other drugs.
Noah L
S C Law Rev; 2002; 54(2):371-403. PubMed ID: 15156891
[TBL] [Abstract][Full Text] [Related]
6. Determinants of vaccine supply.
Natl Bur Econ Res Bull Aging Health; 2011; (3):2-3. PubMed ID: 22207917
[No Abstract] [Full Text] [Related]
7. Medicine. The intangible value of vaccination.
Rappuoli R; Miller HI; Falkow S
Science; 2002 Aug; 297(5583):937-9. PubMed ID: 12169712
[No Abstract] [Full Text] [Related]
8. The politics of vaccine production.
Sauri MA
Md Med; 2005; 6(1):19-22. PubMed ID: 15869102
[No Abstract] [Full Text] [Related]
9. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
DerGurahian J
Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373
[No Abstract] [Full Text] [Related]
10. Markets and public health: pushing and pulling vaccines into production.
Wynia MK
Am J Bioeth; 2006; 6(3):3-6. PubMed ID: 16754439
[No Abstract] [Full Text] [Related]
11. Pharmaceutical industry wins "round one" in protections against product liability claims.
Gatty B
Hosp Formul; 1995 Apr; 30(4):238, 237. PubMed ID: 10141868
[No Abstract] [Full Text] [Related]
12. The U.S. vaccine supply.
Hinman AR
N Engl J Med; 2005 Mar; 352(10):1046-7; author reply 1046-7. PubMed ID: 15758020
[No Abstract] [Full Text] [Related]
13. Strengthening the supply of routinely administered vaccines in the United States: progress and problems--2005.
Klein JO; Helms CM
Clin Infect Dis; 2006 Mar; 42 Suppl 3():S145-50. PubMed ID: 16447138
[No Abstract] [Full Text] [Related]
14. The "tone at the top": can it mitigate C-suite personal liability?
Page GV; Waring MA; Kaiser GR; Cornish K
Food Drug Law J; 2008; 63(3):723-34. PubMed ID: 19031671
[No Abstract] [Full Text] [Related]
15. The U.S. vaccine supply.
Schwartz HK
N Engl J Med; 2005 Mar; 352(10):1046-7; author reply 1046-7. PubMed ID: 15762001
[No Abstract] [Full Text] [Related]
16. Litigation plays protective role--and is part of the problem.
Kennett JD
Mo Med; 2007; 104(1):12-3. PubMed ID: 17410818
[No Abstract] [Full Text] [Related]
17. Authorized generics.
Glass G
Nat Rev Drug Discov; 2005 Dec; 4(12):953-4. PubMed ID: 16370080
[No Abstract] [Full Text] [Related]
18. Immunity for immunizations: tort liability, biodefense, and Bioshield II.
Mayer L
Stanford Law Rev; 2007 Apr; 59(6):1753-90. PubMed ID: 17593591
[No Abstract] [Full Text] [Related]
19. The impact of globalization on vaccine development and availability.
Milstien JB; Kaddar M; Kieny MP
Health Aff (Millwood); 2006; 25(4):1061-9. PubMed ID: 16835187
[TBL] [Abstract][Full Text] [Related]
20. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
Shea LL; Hanson A; Guglielmetti TM; Levy K
Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
[No Abstract] [Full Text] [Related]
[Next] [New Search]
